Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia
- PMID: 26387758
- DOI: 10.1002/uog.15750
Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia
Abstract
Objectives: To investigate longitudinal changes in maternal serum levels of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) in pregnant women who develop pre-eclampsia (PE) or gestational hypertension (GH).
Methods: This was a prospective longitudinal study in women with singleton pregnancies identified by screening at 11 + 0 to 13 + 6 weeks' gestation as being at high-risk of PE. Blood samples were taken every 4 weeks until delivery. Values were compared in women who developed preterm PE (requiring delivery before 37 weeks' gestation), term PE or GH and those who remained normotensive.
Results: A total of 1069 samples were analyzed in 234 women, including 172 who remained normotensive, 18 who developed GH, 22 who developed preterm PE and 22 who developed term PE. In the preterm PE group, compared to the normotensive group, sFlt-1 levels were significantly higher from 15 weeks' gestation onward and the difference increased with gestational age (P < 0.001). In the preterm PE group, compared to the normotensive group, PlGF levels were significantly lower from 11 weeks' gestation onward and the difference increased significantly with gestational age (P < 0.001). Similarly, in the term PE and GH groups, PlGF levels were lower from 13 and 27 weeks onward, respectively, and the differences increased significantly with gestational age (P < 0.001 for both groups). In the preterm PE group, compared to the normotensive group, the sFlt-1/PlGF ratio was significantly higher from 11 weeks onward and the difference increased significantly with gestational age (P < 0.001). A random slope model provided a significantly better fit to the data than did a single-level model for sFlt-1 (likelihood ratio (LR) = 516; degrees of freedom (df) = 3; P < 0.001), PlGF (LR = 542; df = 3; P < 0.001) and the sFlt-1/PlGF ratio (LR = 468; df = 3; P < 0.001).
Conclusion: Repeat measurements of the biochemical markers used in this study are likely to be better predictors of PE than are measurements at a single time point during pregnancy, as the differences between normotensive and hypertensive pregnancies increase with gestational age. In screening for preterm PE, maternal serum level of PlGF is a useful marker from the first trimester onward, while the level of sFlt-1 is likely to have a predictive value from the second trimester onward. Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.
Keywords: blood pressure; gestational hypertension; placental growth factor; pre-eclampsia; pregnancy screening; soluble fms-like tyrosine kinase-1.
Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.
Similar articles
-
Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.Ultrasound Obstet Gynecol. 2018 Jun;51(6):751-757. doi: 10.1002/uog.17547. Epub 2018 May 6. Ultrasound Obstet Gynecol. 2018. PMID: 28600845
-
Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.Ultrasound Obstet Gynecol. 2017 Feb;49(2):209-212. doi: 10.1002/uog.17310. Epub 2017 Jan 6. Ultrasound Obstet Gynecol. 2017. PMID: 27671743
-
Screening for pre-eclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks' gestation.Ultrasound Obstet Gynecol. 2024 Jan;63(1):88-97. doi: 10.1002/uog.27481. Ultrasound Obstet Gynecol. 2024. PMID: 37724582
-
Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis.Health Technol Assess. 2016 Nov;20(87):1-160. doi: 10.3310/hta20870. Health Technol Assess. 2016. PMID: 27918253 Free PMC article. Review.
-
Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction.Ultrasound Obstet Gynecol. 2023 Feb;61(2):168-180. doi: 10.1002/uog.26032. Ultrasound Obstet Gynecol. 2023. PMID: 35816445 Review.
Cited by
-
The impact of first-trimester subchorionic hematomas on pregnancy outcomes after euploid embryo transfer: a retrospective cohort study.BMC Pregnancy Childbirth. 2024 Mar 7;24(1):180. doi: 10.1186/s12884-024-06359-5. BMC Pregnancy Childbirth. 2024. PMID: 38454339 Free PMC article.
-
Prenatal screening for preeclampsia: the roles of placental growth factor and pregnancy-associated plasma protein A in the first trimester and placental growth factor and soluble fms-like tyrosine kinase 1-placental growth factor ratio in the early second trimester.AJOG Glob Rep. 2023 Mar 11;3(2):100193. doi: 10.1016/j.xagr.2023.100193. eCollection 2023 May. AJOG Glob Rep. 2023. PMID: 37168546 Free PMC article.
-
Preeclampsia at term can be classified into 2 clusters with different clinical characteristics and outcomes based on angiogenic biomarkers in maternal blood.Am J Obstet Gynecol. 2023 May;228(5):569.e1-569.e24. doi: 10.1016/j.ajog.2022.11.001. Epub 2022 Nov 3. Am J Obstet Gynecol. 2023. PMID: 36336082 Free PMC article.
-
Model for Early Prediction of Preeclampsia: A Nested Case Controlled Study in Indian Women.J Obstet Gynaecol India. 2022 Aug;72(4):299-306. doi: 10.1007/s13224-021-01511-z. Epub 2021 Jun 29. J Obstet Gynaecol India. 2022. PMID: 35923506 Free PMC article.
-
High early pregnancy body mass index is associated with alterations in first- and second-trimester angiogenic biomarkers.Am J Obstet Gynecol MFM. 2022 May;4(3):100614. doi: 10.1016/j.ajogmf.2022.100614. Epub 2022 Mar 10. Am J Obstet Gynecol MFM. 2022. PMID: 35283347 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous